Collagen Market Enters the GLP-1 Era as Nextida Reshapes Supply | NextMSC

Introduction

The global collagen peptide and gelatin market is undergoing a structural transformation — one driven not merely by incremental consumer demand, but by a convergence of pharmaceutical-grade clinical validation, landmark supply-side consolidation, and the emergence of collagen as a functional metabolic health ingredient. According to Next Move Strategy Consulting's Collagen Peptide and Gelatin Market report, the global collagen peptide and gelatin market was valued at USD 4.61 billion in 2022 and is projected to reach USD 7.25 billion by 2030, growing at a CAGR of 6.1% from 2023 to 2030. 

This trajectory is no longer anchored solely to the confectionery and cosmetics sectors that historically defined gelatin and collagen peptide demand. The market is being reshaped by two simultaneous forces: a USD 1.5 billion supply-side merger that will consolidate nearly 200,000 metric tons of global production capacity under a single joint venture, and a clinically validated collagen peptide composition that has demonstrated the ability to naturally stimulate GLP-1 hormone secretion — placing collagen squarely within the fastest-growing segment of the global nutraceutical industry. For C-level executives and institutional investors evaluating this space, the strategic window is narrowing.

For More Information: Download FREE Sample on Collagen Peptide and Gelatin Market Report

The Nextida Formation and the GLP-1 Collagen Breakthrough: Two Forces Redefining the Market

A USD 1.5 Billion Consolidation Reshapes Global Supply

On May 12, 2025, Darling Ingredients and Tessenderlo Group announced a non-binding term sheet to combine their collagen and gelatin businesses into Nextida. The parties signed the definitive agreement on December 10, 2025— Rousselot and PB Leiner — into a new joint venture named Nextida™. Darling Ingredients holds an 85% majority stake, with Tessenderlo Group retaining the remaining 15%. The transaction requires no cash outlay from either party, combining assets, capabilities, and geographic infrastructure rather than financial consideration. 

The resulting entity will command approximately USD 1.5 billion in annual revenue and approximately 200,000 metric tons of combined gelatin and collagen production capacity across 23 facilities spanning South America, North America, Europe, and Asia — a geographic footprint that no single competitor currently matches. 

"Collagen has represented the fastest-growing area of Darling Ingredients' food segment business over the past several years, and with the addition of PB Leiner's people, assets and products, we are well positioned to increase scale and focus in this rapidly growing segment," said Randall C. Stuewe, Chairman and Chief Executive Officer of Darling Ingredients, in the company's official announcement on May 12, 2025. 

Luc Tack, Chief Executive Officer of Tessenderlo Group, added: "With this combination, we will have the best new ownership possible. We will benefit from each other by sharing technology expertise and providing a complementary offering for our global customer base. This includes many in-demand products, such as gelatin and collagen peptides." 

The transaction is pending regulatory approvals and was expected to close in 2026. Its significance extends beyond scale: by eliminating the commercial and logistical redundancies between two of the world's largest collagen producers, Nextida is positioned to redirect capital toward targeted product development — a strategic pivot that directly intersects with the market's most consequential emerging application.

Nextida GC: Collagen Enters the GLP-1 Era

At Natural Products Expo West 2026 in Anaheim, California (March 3–6), Rousselot showcased its Nextida GC collagen peptide composition alongside its established Peptan brand, with a specific focus on metabolic health applications and GLP-1 support. The event marked a pivotal moment for the collagen peptide and gelatin market: for the first time, a specific collagen peptide composition had completed two human clinical studies demonstrating measurable effects on postprandial glucose control and incretin hormone secretion.

Lauretta Katsriku, Global Category Leader, Collagen at Rousselot, confirmed at Expo West 2026 that the second clinical study validated findings from the first: "This study actually confirms that the consumption of Nextida GC prior to a carb heavy meal actually has specific postprandial glucose control benefits. It actually also shows an increase in GLP-1 secretion upon intake, as well as a sustained GLP-1 level up to about two hours after intake. Very interesting enough as well, this study actually confirmed that there was a significant delay in gastric emptying in a specific pre-diabetic cohort." 

The clinical protocol involved participants consuming either 5 grams or 10 grams of Nextida GC 30 minutes before a carbohydrate-heavy meal. The composition was also granted a U.S. patent protecting its specific bioactive collagen peptide formulation for metabolic health applications — a development that Katsriku described as substantiating Rousselot's "strategy in advancing beyond collagen peptides in structural applications to targeted, specific health, functional benefits." 

The commercial implications are direct. According to a Kaiser Family Foundation Health Tracking Poll cited by Florencia Moreno Torres, Global Marketing Manager at Rousselot, approximately 1 in 8 adults (12%) in the United States are currently taking a GLP-1 drug for weight loss, diabetes, or another condition — a figure that has risen substantially over the preceding 18 months. A Rousselot consumer survey conducted in 2025 found that among individuals who discontinued GLP-1 treatments, 31% reported that most of the weight they had lost returned, and 32% reverted to prior eating habits — identifying a substantial post-treatment maintenance market for functional collagen formulations. 

NMSC Strategic Perspective: What These Developments Signal for Market Structure

NextMSC primary research and analysis identifies the Nextida formation and the Nextida GC clinical validation as structurally linked events, not coincidental developments. The consolidation of Rousselot and PB Leiner under a single entity creates the production scale and R&D investment capacity required to commercialize clinically validated, patent-protected collagen compositions at the volumes that mass-market nutraceutical and functional food applications demand. The GLP-1 adjacency is particularly significant: it repositions collagen peptides from a passive structural ingredient — consumed for skin hydration or joint support — into an active metabolic health ingredient with a measurable, patented mechanism of action. This distinction matters for pricing power, regulatory positioning, and the addressable customer base. Brands formulating GLP-1 companion products represent a new buyer category that did not exist in the collagen peptide market three years ago.

Section Summary:

• Darling Ingredients and Tessenderlo Group are forming Nextida™, a ~USD 1.5 billion revenue joint venture combining Rousselot and PB Leiner, with 200,000 metric tons of capacity across 23 global facilities.

• Rousselot's Nextida GC received a U.S. patent and completed a second human clinical study confirming postprandial glucose control, GLP-1 secretion stimulation, and delayed gastric emptying in prediabetic participants.

• Approximately 1 in 8 U.S. adults currently use GLP-1 drugs, and a Rousselot 2025 consumer survey found 31% of those who stopped treatment regained most of their lost weight — defining a new addressable market for functional collagen formulations.

• NMSC analysis identifies the Nextida consolidation as the supply-side infrastructure required to scale clinically validated, patent-protected collagen compositions into mass-market functional food and nutraceutical channels.

Industry Impact Analysis

The Aging Population Imperative

The structural demand case for collagen peptide and gelatin products is reinforced by demographic data that is both well-established and accelerating. According to the World Health Organization, the number of persons aged 80 years or older is expected to triple between 2020 and 2050, reaching 426 million globally. This demographic shift directly expands the addressable market for collagen-based bone, joint, and skin health products, as collagen synthesis in the human body declines measurably with age.

The International Osteoporosis Foundation reports that osteoporosis — a condition in which collagen-rich bone matrix deteriorates — affects 1 in 3 women and 1 in 5 men over the age of 50 globally. Gelatin's lysine content, which supports calcium absorption and bone density maintenance, positions it as a functional ingredient in the pharmaceutical and nutraceutical formulations targeting this population. As the over-50 demographic expands across North America, Europe, and Asia-Pacific simultaneously, the demand for collagen peptide and gelatin products in healthcare and nutraceutical applications is structurally supported rather than trend-dependent.

Marine Collagen: The Fastest-Growing Source Segment

Within the collagen peptide and gelatin market, the marine source segment is registering the highest growth velocity. Marine collagen — derived from fish skin, scales, and bones — addresses two converging consumer demands: the preference for non-bovine and non-porcine collagen sources among Muslim, Jewish, and vegetarian-adjacent consumers, and the growing emphasis on sustainability and traceability in ingredient sourcing.

The marine collagen segment's growth is also being reinforced by the pharmaceutical sector's interest in its bioavailability profile. Marine collagen peptides, with their lower molecular weight compared to bovine-derived equivalents, demonstrate faster absorption rates — a characteristic that is increasingly relevant as clinical applications of collagen peptides expand beyond cosmetics into metabolic health and wound care.

The Functional Food and Beverage Channel: Blurring the Supplement Boundary

Florencia Moreno Torres, Global Marketing Manager at Rousselot, articulated a structural shift in consumer behavior at Expo West 2026: "For consumers, the line between supplements and functional food and beverages is blurring. As a result, people are showing increased interest in food and beverages that offer the benefits they would have normally received from supplements." The launch of Byon — a beauty-and-performance beverage combining Peptan and Nextida GC, first introduced in Austria — exemplifies this convergence, demonstrating that collagen peptide formulations can simultaneously carry beauty-from-within and metabolic health claims within a single consumer product. 

This channel shift has direct implications for distribution strategy. E-commerce platforms — including Amazon, Walmart, and iHerb — have materially lowered the barrier to entry for collagen supplement brands, enabling smaller, science-backed brands to reach health-conscious consumers without the shelf-space constraints of traditional retail. According to NextMSC primary research and analysis, the e-commerce distribution channel represents one of the most significant structural growth levers for the collagen peptide and gelatin market through 2030.

Section Summary:

• The WHO projects the global population aged 80+ will triple to 426 million by 2050, directly expanding the addressable market for collagen-based bone, joint, and skin health formulations.

• The International Osteoporosis Foundation estimates osteoporosis affects 1 in 3 women and 1 in 5 men over 50 globally, reinforcing pharmaceutical and nutraceutical demand for gelatin and collagen peptide ingredients.

• Marine collagen is the fastest-growing source segment, driven by religious dietary compliance, sustainability preferences, and superior bioavailability in clinical applications.

• The functional food and beverage channel is absorbing demand previously served by standalone supplements, with multi-claim collagen beverages like Byon demonstrating the commercial viability of this convergence.

Pros and Cons of Recent Market Developments

Key Data & Statistics

Key Industry Developments and Competitive Events (2025–2026)